AstraZeneca PLC (AZN.L)
|Market Cap (Mil.):||£54,170.24|
|Shares Outstanding (Mil.):||1,262.59|
* FTSE 100 up 0.2 pct, near 3-week high * AstraZeneca up on speculation over new Pfizer bid * Miners lag after weak Chinese data By Sudip Kar-Gupta LONDON, Aug 21 - Britain's top equity index rose on Thursday on gains in healthcare stocks, led by AstraZeneca on speculation rejected U.S. suitor Pfizer might make another bid. The blue-chip FTSE 100 index was up by 0.2 percent, or 10.83 points, at 6,766.31 points in early trading, approaching three-week highs touched
LONDON - AstraZeneca and Mitsubishi Tanabe Pharma said on Wednesday they said signed a three-year research collaboration into diabetic nephropathy, or kidney failure due to diabetes.
LONDON, Aug 20 - AstraZeneca and Mitsubishi Tanabe Pharma said on Wednesday they said signed a three-year research collaboration into diabetic nephropathy, or kidney failure due to diabetes.
LONDON - The U.S. government has cleared AstraZeneca Plc over a major clinical trial used to win marketing approval for its important new heart drug Brilinta, following an investigation which had cast a shadow over its prospects.
* Company hopes for new data in Dec to support expanded use
LONDON, Aug 19 - AstraZeneca said on Tuesday the U.S. government was closing a probe into a major clinical trial used to win marketing approval for its new heart drug Brilinta and no further action was planned.
* Announces positive top-line results from phase III programme of CAZ-AVI
LONDON, Aug 13 - AstraZeneca, which fended off a $118 billion takeover approach from Pfizer in May, reported positive results for an experimental gout drug on Wednesday that could boost its sales modestly.
LONDON, Aug 13 - British drugmaker AstraZeneca said on Wednesday that test results indicated that lesinurad, a selective uric acid re-absorption inhibitor, used in combination could be a potential treatment for gout.
LONDON - Could Pfizer acquire GlaxoSmithKline as a "plan B" after failing to land AstraZeneca ? It would be a stretch but not totally impossible, according to analysts at Berenberg Bank.
Earnings vs. Estimates
Analyst Research Reports
Provider: Thomson Reuters Stock Report
"The Economy Matters" Report for AZN: the economy's impact on AZN's price and risk, featuring the powerful Economic Climate Rating
Provider: MacroRisk Analytics/EconomicInvestor
Provider: ValuEngine, Inc.
Provider: S&P Capital IQ – STARS Reports
AstraZeneca PLC: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.